Amendments to the Claims

1. (previously presented) A benzisothiazole-3(2H)-one compound of formula (I)



(I)

wherein;

R_1 is the group (C_4-C_{12})haloalkyl, -CF_3, (C_1-C_8)alkylcycloalkyl, or (C_3-C_8)cycloalkyl, ;

R_2 is hydrogen;

R_3, R_4, R_5, and R_6, are each independently selected from hydrogen, (C_1-C_4)alkyl, (C_2-C_4)alkenyl, -O-(C_1-C_3 alkyl), COOH, C(O)(C_1-C_3 alkyl), C(O)O(C_1-C_3 alkyl), -CF_3, and halo; or a pharmaceutically acceptable salt thereof.

2. (canceled)

3. (previously presented) A compound according to Claim 1 wherein R_1 is (C_3-C_4)alkylcycloalkyl, or -CF_3.

4. (canceled)

5. (canceled)

6. (previously presented) The compound of Claim 1 wherein R_5 is the group represented by chloro, bromo or CF_3.

7. (previously presented) A compound selected from the group consisting of:

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid allylamide;

~~3~~-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid cyclohexylamide;

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (4-cyclohexyl-butyl)-amide; and

6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid cyclohexylamide.

8. (canceled)

9. (previously presented) A pharmaceutical formulation comprising a benzisothiazole-3(2H)-one compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.

10-15. (canceled)

16. (previously presented) The method of claim 18 wherein the benzisothiazole-3(2H)-one compound is formulated with a pharmaceutically acceptable carrier or diluent.

17. (canceled)

18. (previously presented) A method of treating hypercholesterolemia, hyperlipidemia, or atherosclerosis in a mammal in need thereof comprising administering a therapeutically effective amount of benzisothiazole-3(2H)-one compound of formula I, wherein R_1-R_6 are as defined in claim 1



I

or a pharmaceutical acceptable salt thereof.